C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-β/smad3 and IKBα pathway
about
The role of the complement system in diabetic nephropathy.Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.A previously unrecognized role of C3a in proteinuric progressive nephropathy.Developing Treatments for Chronic Kidney Disease in the 21st Century.The next generation of therapeutics for chronic kidney diseaseTargeting the complement cascade: novel treatments coming down the pike.High glucose/lysophosphatidylcholine levels stimulate extracellular matrix deposition in diabetic nephropathy via platelet‑activating factor receptor.The clinical implications of the unique glomerular complement deposition pattern in transplant glomerulopathy.Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice.Protective effect of L-glutamine against diabetes-induced nephropathy in experimental animal: Role of KIM-1, NGAL, TGF-β1, and collagen-1.Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway.Blood glucose fluctuation accelerates renal injury involved to inhibit the AKT signaling pathway in diabetic rats.Protective effects of leflunomide on renal lesions in a rat model if diabetic nephropathy.Complement Activation in Patients With Diabetic Nephropathy.C3a triggers formation of sub-retinal pigment epithelium deposits via the ubiquitin proteasome pathway.
P2860
Q30235417-BBC6F4AA-9ABC-46C5-8B32-18E71D27552FQ36913772-89484A78-3A9C-49F0-AD00-1C935C4ADBB9Q37040241-ADA58136-1525-477A-93FF-7E7600B29B01Q38781550-541CD649-A0E3-4498-AB6B-E9705E149F53Q38845590-80EF26DD-A7EB-42BB-AE14-275589E99C81Q38850489-6189776C-7A50-4C9B-ADD9-4A50F1523389Q47329024-D2B13FB8-6509-41E8-8B14-54951668FA1BQ48224009-FD6E2151-E2AC-4CCB-AC34-712317FE8F0FQ50225628-1FDB19FB-29F2-4BAA-B309-68104FEB4689Q51378901-BFD3AFEB-D0E6-4A63-9A48-72B9D8DD5677Q52684055-3881C4E7-FDD5-4EA6-8139-E20A02D28988Q53179601-A0C489D7-324E-48ED-A2FF-9C0565A39720Q53296448-39FC67F4-3E7F-491A-9E5C-64C7B808B740Q54969005-61717E5C-8C48-4E7B-85E4-B90539D8BBC7Q55426544-23766A94-32C0-4E6F-B3ED-F93BD1C5CD9E
P2860
C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-β/smad3 and IKBα pathway
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
C3a receptor antagonist amelio ...... f TGF-β/smad3 and IKBα pathway
@ast
C3a receptor antagonist amelio ...... f TGF-β/smad3 and IKBα pathway
@en
C3a receptor antagonist amelio ...... f TGF-β/smad3 and IKBα pathway
@nl
type
label
C3a receptor antagonist amelio ...... f TGF-β/smad3 and IKBα pathway
@ast
C3a receptor antagonist amelio ...... f TGF-β/smad3 and IKBα pathway
@en
C3a receptor antagonist amelio ...... f TGF-β/smad3 and IKBα pathway
@nl
prefLabel
C3a receptor antagonist amelio ...... f TGF-β/smad3 and IKBα pathway
@ast
C3a receptor antagonist amelio ...... f TGF-β/smad3 and IKBα pathway
@en
C3a receptor antagonist amelio ...... f TGF-β/smad3 and IKBα pathway
@nl
P2093
P2860
P3181
P1433
P1476
C3a receptor antagonist amelio ...... f TGF-β/smad3 and IKBα pathway
@en
P2093
Hongping Zhu
Jingqiu Cheng
Qinghua Yin
Shenju Gou
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0113639
P407
P577
2014-01-01T00:00:00Z